HF prevalence and evolution of HF in DM II patients at high risk

Trial Identifier: D1843R00313
Sponsor:AstraZeneca
NCTID:NCT04482283
Start Date:July 2020
Primary Completion Date: November 2024
Study Completion Date: November 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

CountryLocation
Greece, D1843R00313 Alexandroupolis, D1843R00313, Greece, 68 100
Greece, D1843R00313 Athens, D1843R00313, Greece, 12 462
Greece, D1843R00313 Athens, D1843R00313, Greece, 115 27
Greece, D1843R00313 Athens, D1843R00313, Greece, 115 28
Greece, D1843R00313 Athens, D1843R00313, Greece, 11 527
Greece, D1843R00313 Athens, D1843R00313, Greece, 10 676
Greece, D1843R00313 Heraklion, D1843R00313, Greece, 71 110
Greece, D1843R00313 Larissa, D1843R00313, Greece, 41 110
Greece, D1843R00313 Patra, D1843R00313, Greece, 26 504
Greece, D1843R00313 Thessaloniki, D1843R00313, Greece, 54 636
Greece, D1843R00313 Thessaloniki, D1843R00313, Greece, 54 642